Last updated: October 2026

AMT-130 (ifezuntirgene inilparvovec) is a one-time gene therapy being developed by uniQure for Huntington’s disease. It is delivered through a neurosurgical procedure and is designed to reduce production of the mutant huntingtin protein.

Current status

Public company and regulatory updates indicate that AMT-130 remains one of the most advanced HD treatment candidates. It is not FDA approved, and availability, eligibility, safety, effectiveness, timing, and cost remain uncertain.

We will update this post as credible trial, regulatory, coverage, or access information becomes available. For the newest coverage across the HD treatment pipeline, visit What’s Happening in HD Treatment.